SG11201802956RA - Colloidal particles for use in medicine - Google Patents

Colloidal particles for use in medicine

Info

Publication number
SG11201802956RA
SG11201802956RA SG11201802956RA SG11201802956RA SG11201802956RA SG 11201802956R A SG11201802956R A SG 11201802956RA SG 11201802956R A SG11201802956R A SG 11201802956RA SG 11201802956R A SG11201802956R A SG 11201802956RA SG 11201802956R A SG11201802956R A SG 11201802956RA
Authority
SG
Singapore
Prior art keywords
medicine
colloidal particles
colloidal
particles
Prior art date
Application number
SG11201802956RA
Other languages
English (en)
Inventor
William Henry
Richard Wolf-Garraway
John Mayo
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of SG11201802956RA publication Critical patent/SG11201802956RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201802956RA 2015-10-14 2016-10-14 Colloidal particles for use in medicine SG11201802956RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518172.0A GB201518172D0 (en) 2015-10-14 2015-10-14 Colloidal particles for use in medicine
PCT/EP2016/074759 WO2017064276A1 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine

Publications (1)

Publication Number Publication Date
SG11201802956RA true SG11201802956RA (en) 2018-05-30

Family

ID=55131025

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201802956RA SG11201802956RA (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine
SG10202010711UA SG10202010711UA (en) 2015-10-14 2016-10-14 Colloidal Particles for Use in Medicine

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202010711UA SG10202010711UA (en) 2015-10-14 2016-10-14 Colloidal Particles for Use in Medicine

Country Status (15)

Country Link
US (3) US20190192664A1 (cg-RX-API-DMAC7.html)
EP (1) EP3362039A1 (cg-RX-API-DMAC7.html)
JP (1) JP7160678B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180067616A (cg-RX-API-DMAC7.html)
CN (1) CN108472246A (cg-RX-API-DMAC7.html)
AU (1) AU2016336929B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018007399A2 (cg-RX-API-DMAC7.html)
CA (1) CA3036111C (cg-RX-API-DMAC7.html)
EA (1) EA201890703A1 (cg-RX-API-DMAC7.html)
GB (1) GB201518172D0 (cg-RX-API-DMAC7.html)
HK (1) HK1256814A1 (cg-RX-API-DMAC7.html)
IL (1) IL258567B2 (cg-RX-API-DMAC7.html)
MX (1) MX391574B (cg-RX-API-DMAC7.html)
SG (2) SG11201802956RA (cg-RX-API-DMAC7.html)
WO (1) WO2017064276A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115190883A (zh) * 2019-11-07 2022-10-14 伊利诺伊大学评议会 治疗脓毒症、动脉粥样硬化、血栓形成、中风、心脏病发作和炎症的肽和方法
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111759D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
GB202111758D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE179599T1 (de) 1993-08-06 1999-05-15 Opperbas Holding Bv Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
ES2233036T3 (es) 1998-04-27 2005-06-01 Opperbas Holding B.V. Composicion farmaceutica que comprende factor viii y liposomas neutros.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
RU2250911C2 (ru) 1999-07-14 2005-04-27 Элзэ Копэрейшн Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы
US20070141135A1 (en) * 2005-06-29 2007-06-21 Balu-Lyer Sathy V Compositions and methods for less immunogenic protein-lipid complexes
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
ATE395101T1 (de) 2003-04-15 2008-05-15 Opperbas Holding Bv Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
EP2437726B1 (en) 2009-06-03 2018-05-16 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
AU2010283998B2 (en) 2009-08-21 2015-01-29 Targeted Delivery Technologies Limited Vesicular formulations
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB2516388A (en) 2012-04-16 2015-01-21 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
JP6352950B2 (ja) * 2013-03-08 2018-07-04 ノバルティス アーゲー 活性薬物の送達のための脂質と脂質組成物

Also Published As

Publication number Publication date
US20250170244A1 (en) 2025-05-29
GB201518172D0 (en) 2015-11-25
CA3036111A1 (en) 2017-04-20
BR112018007399A2 (pt) 2018-10-16
EP3362039A1 (en) 2018-08-22
SG10202010711UA (en) 2020-12-30
EA201890703A1 (ru) 2018-11-30
IL258567B1 (en) 2025-04-01
HK1256814A1 (zh) 2019-10-04
IL258567B2 (en) 2025-08-01
MX391574B (es) 2025-03-21
US20210093721A1 (en) 2021-04-01
CN108472246A (zh) 2018-08-31
AU2016336929B2 (en) 2022-09-29
US20190192664A1 (en) 2019-06-27
JP2018535952A (ja) 2018-12-06
KR20180067616A (ko) 2018-06-20
IL258567A (en) 2018-05-31
MX2018004445A (es) 2018-08-14
JP7160678B2 (ja) 2022-10-25
AU2016336929A1 (en) 2018-05-10
WO2017064276A1 (en) 2017-04-20
CA3036111C (en) 2023-06-06

Similar Documents

Publication Publication Date Title
GB2524085B (en) Exception handling in microprocessor systems
IL252532A0 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical use
SG11201605896WA (en) Dihydropyrimidine compounds and their application in pharmaceuticals
PL3046983T3 (pl) Wielowarstwowa cząstka ścierna
SG11201700968PA (en) Formulation comprising particles
ZA201502203B (en) Nano particulate delivery system
IL251630A0 (en) Combined therapy for use in cancer treatment
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
IL251905B (en) Epilimod for use in the treatment of kidney cancer
IL250507A0 (en) Anti-ck8 antibodies for use in cancer therapy
EP3177304A4 (en) Therapeutic nanoparticles for accumulation in the brain
IL248424A0 (en) Neuroprotective substances and their uses
GB201521304D0 (en) Tokenisation in cardholder - not - present transactions
SG11201606034WA (en) Device for delivering particles
GB201701400D0 (en) Compound for use in medicine
IL258567A (en) Colloidal particles for use in medicine
PL3129057T3 (pl) Glikolipidy i ich kompozycje farmaceutyczne do stosowania w leczeniu
GB201516107D0 (en) Complexes and methods for their preparation
GB201616880D0 (en) Compound for use in medicine
GB201701388D0 (en) Compound for use in medicine
GB201416493D0 (en) Polypeptides for use in therapy
GB201404831D0 (en) Animalistic studies in nature
GB201409978D0 (en) Novel compounds and their use in therapy